期刊文献+

Thromboembolic event rate in patients with persistent or paroxysmal atrial fibrillation post circumferential pulmonary vein isolation:a single center experience in China 被引量:1

Thromboembolic event rate in patients with persistent or paroxysmal atrial fibrillation post circumferential pulmonary vein isolation:a single center experience in China
原文传递
导出
摘要 Background Pulmonary-vein isolation (PVI) is currently used for the treatment of chronic and paroxysmal atrial fibrillation and a major risk of PVI is thromboembolism. The purpose of this study was to observe embolic event rate in patients with persistent or paroxysmal atrial fibrillation (AF) undergone PVI. Methods Circumferential PVI (CPVI) was performed in 64 consecutive patients with persistent AF (42 men, aged (60.0 ±9.1) years) and in 84 consecutive patients with paroxysmal AF (53 men, aged (61.4±9.3) years). Warfarin was administrated in all patients before ablation for at least 3 weeks ((5.2±2.6) weeks) and continued for at least 3 months post ablation with international normalized ratio (INR) of 2.0-3.0. During CPVI, intravenous heparin was given at a dose of 5000-8000 U or 75-100 U/kg, followed by 1000 U or 12 U/kg per hour. Results In patients with persistent AF, 1 patient developed embolic event during ablation and 3 patients developed embolic events after ablation. In contrast, no thromboembolic event was observed in patients with paroxysmal AF (4/64 vs 0/84, P=-0. 033). Conclusion Thromboembolic event rate related to CPVl is significantly higher in patients with persistent AF than that in patients with paroxysmal AF. Background Pulmonary-vein isolation (PVI) is currently used for the treatment of chronic and paroxysmal atrial fibrillation and a major risk of PVI is thromboembolism. The purpose of this study was to observe embolic event rate in patients with persistent or paroxysmal atrial fibrillation (AF) undergone PVI. Methods Circumferential PVI (CPVI) was performed in 64 consecutive patients with persistent AF (42 men, aged (60.0 ±9.1) years) and in 84 consecutive patients with paroxysmal AF (53 men, aged (61.4±9.3) years). Warfarin was administrated in all patients before ablation for at least 3 weeks ((5.2±2.6) weeks) and continued for at least 3 months post ablation with international normalized ratio (INR) of 2.0-3.0. During CPVI, intravenous heparin was given at a dose of 5000-8000 U or 75-100 U/kg, followed by 1000 U or 12 U/kg per hour. Results In patients with persistent AF, 1 patient developed embolic event during ablation and 3 patients developed embolic events after ablation. In contrast, no thromboembolic event was observed in patients with paroxysmal AF (4/64 vs 0/84, P=-0. 033). Conclusion Thromboembolic event rate related to CPVl is significantly higher in patients with persistent AF than that in patients with paroxysmal AF.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2007年第11期956-959,共4页 中华医学杂志(英文版)
基金 the National Natural Science Foundation of China(No. 30200201)
关键词 atrial fibrillation catheter ablation THROMBOSIS THROMBOEMBOLISM atrial fibrillation catheter ablation thrombosis thromboembolism
  • 相关文献

参考文献1

二级参考文献14

  • 1Haissaguerre M, Jais P, Shah DC, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci[J]. Circulation, 2000, 101:1 409
  • 2Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation[J]. Circulation, 2002, 105:1 077
  • 3Yamane T, Shah DC, Jais P, et al. Electrogram polarity reversal as an additional indicator of breakthroughs from the left atrium to the pulmonary veins[J]. J Am Coll Cardiol, 2002, 39:1 337
  • 4Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy[J]. J Am Coll Cardiol, 2003, 41:1 633
  • 5Wenger NK. Atrial fibrillation at elderly age: The importance of stroke prevention[J]. Am J Geriatr Cardiol, 1997, 6:35
  • 6Roijer A, Eskilsson J, Olsson B. Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion[J]. Eur Heart J, 2000, 21:837
  • 7Spandorfer J. The management of anticoagulation before and after procedures[J]. Med Clin North Am, 2001, 85:1 109
  • 8Al-Khadra AS. Implantation of pacemakers and implantable cardioverter defibrillators in orally anticoagulated patients[J]. PACE, 2003,26:511
  • 9Gronefeld GC, Wegener F, Israel CW, et al. Thromboembolic risk of patients referred for radiofrequency catheter ablation of typical atrial flutter without prior appropriate anticoagulation therapy[J]. PACE, 2003,26:323
  • 10Cauchemez B, Extramiana F, Cauchemez S, et al. High-flow perfusion of sheaths for prevention of thromboembolic complications during complex catheter ablation in the left atrium[J]. J Cardiovasc Electrophysiol, 2004,15:276

共引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部